Current Environment:

Summary

The purpose of this study is to examine whether the duration of treatment with phenobarbital has an impact on neurodevelopmental and epilepsy outcomes, as well as parent and family well-being, after neonatal seizures.

Conditions

Neonatal Seizures

Recruitment Status

Completed

Eligibility Criteria

Inclusion Criteria:

Neonates <44 weeks corrected age at seizure onset
Seizures due to acute brain injury
Parent(s) who are English or Spanish literate (with assistance of interpreter)

Exclusion Criteria:

Neonates at risk for adverse outcome independent of seizures and underlying brain injury
Neonates with mild, temporary causes for seizures
Newborns with neonatal-onset epilepsy syndromes
Neonates who do not survive the initial hospital admission
Neonates will not be excluded based on race, ethnicity, gender or gestational age

Intervention

Intervention Type

Intervention Name

Other

Surveys

Other

EEG

Gender

All

Min Age

0 Weeks

Max Age

24 Months

Download Date

December 4, 2020

Principal Investigator

Renée Shellhaas, MD

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study NCT02789176